Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric Trial
Latest Information Update: 16 Feb 2024
At a glance
- Drugs Pasireotide (Primary)
- Indications Peritoneal cancer
- Focus Therapeutic Use
- Acronyms PASIREOCHIP
Most Recent Events
- 15 Feb 2024 This trial has been completed, according to the European Clinical Trials Database record.
- 07 Feb 2024 Status changed from suspended to discontinued.
- 16 May 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Jul 2023.